Company to present at the Rodman and Renshaw 11th Annual Healthcare Conference
LAVAL, QC, Sept. 8 /CNW Telbec/ - BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX: BLU) today disclosed the results of its previously announced rights offering. The Company will raise an aggregate of C$9,687,233 from the rights offering and issue a total of 52,363,419 common shares at a price of C$0.185 per share (the "Subscription Price").
Under the rights offering, rights were exercised to subscribe for 9,120,177 common shares at the Subscription Price for proceeds of C$1,687,233. Additionally, in accordance with the terms of the stand-by purchase agreements entered into by BELLUS Health with Vitus Investments III Private Limited ("Vitus") and Victoria Square Ventures Inc. ("VSVI"), each of Vitus and VSVI will subscribe for 21,621,621 common shares of BELLUS Health at the Subscription Price for an aggregate of C$8,000,000.
The Company's transfer agent is in the process of distributing shares to those shareholders who participated in the rights offering, either directly or through their brokers. Closing of the rights offering is expected to occur on Thursday, September 10.
This press release is not an offer to sell or a solicitation of an offer to buy any securities of the Company.
The securities will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States.
Presentation at Rodman and Renshaw Investor Conference
The Company also announces that on Friday, September 11, Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of BELLUS Health Inc., will present an update and review of ongoing pharmaceutical and nutraceutical activities at the Rodman and Renshaw 11th Annual Healthcare Conference to be held at the New York Palace Hotel in New York, NY. The presentation will take place at 9:10 A.M. ET in the Henry Salon, located on the 5th floor of the hotel.
About BELLUS Health
BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.
To contact BELLUS Health
For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1 877 680 4500 or visit the Web Site at www.bellushealth.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business.